Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088932 | 0.84 | KDM5A (0.62) | PRKCIKDM5ANPC1MAPTPOLB | |
| SCHEMBL1545415 | 0.84 | PRKCI (0.59) | PRKCIPKMAKR1C3AKR1C2KDM5A | |
| SCHEMBL20630760 | 0.83 | PRKCI (0.69) | PRKCIPKMAKR1C3AKR1C2NPC1 | |
| SCHEMBL3715569 | 0.82 | POLB (0.67) | PRKCIPKMAKR1C3AKR1C2KDM5A | |
| SCHEMBL13847151 | 0.81 | CA1 (0.67) | MAPTPOLBHTTKMT2ACA12 | |
| SCHEMBL19405908 | 0.81 | NPC1 (0.50) | PRKCIPKMAKR1C3AKR1C2KDM5A | |
| SCHEMBL15075228 | 0.80 | PRKCI (0.65) | PRKCIAKR1C3AKR1C2NPC1MAPT | |
| SCHEMBL28385567 | 0.80 | PRKCI (0.65) | PRKCIAKR1C3AKR1C2 | |
| SCHEMBL10030689 | 0.79 | MAPT (0.57) | PRKCINPC1MAPTRAB9APOLB | |
| SCHEMBL912924 | 0.78 | PRKCI (0.62) | PRKCIPKMAKR1C3AKR1C2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426504-B2 | Hardenable epoxy resin composition | ADEKA CORPORATION (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8153260-B2 | Composite material | ADEKA CORPORATION (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20100190899-A1 | HARDENABLE EPOXY RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100112323-A1 | COMPOSITE MATERIAL | ADEKA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-0989986-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | Abbott Laboratories (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, OPRM1 | PRKCI 2031/4885PKM 2939/4885AKR1C3 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.